CIBA's PRISCOLINE (TOLAZOLINE) IS DESI-EFFECTIVE IN NEONATES
CIBA's PRISCOLINE (TOLAZOLINE) IS DESI-EFFECTIVE IN NEONATES with persistent pulmonary hypertension, but lacks "substantial evidence of effectiveness" for other labeled indications, FDA said in an Aug. 28 Federal Register notice. Under the DESI review program, FDA classified Priscoline in 1979 as lacking substantial evidence of effectiveness in treating spastic peripheral vascular disorders associated with a number of diseases. While that status has not changed, FDA noted that the agency and Ciba-Geigy "became aware that there was a potential critical medical need for Priscoline Inj. in treating neonates with pulmonary vasocontriction and hypertension." Since 1979, Ciba has supplemented its NDA with published studies in support of this use, FDA said. Under the new approved labeling, Priscoline is now indicated "for the treatment of persistent pulmonary hypertension of the newborn ('persistent fetal circulation') when systemic arterial oxygenation cannot be satisfactorily maintained by usual supportive care (supplemental oxygen and/or mechanical ventilation)." The labeling adds that Priscoline "should be used in a highly supervised setting, where vital signs, oxygenation, acid base status, and fluid electrolytes can be monitored and maintained." The revised "dosage and administration" section reads: "An initial dose of 1 to 2 mg/kg via scalp vein, followed by infusion have usually resulted in significant increases in arterial oxygen." Ciba-Geigy has until the end of October to file a supplemental NDA and until the end of the year to revise the labeling, the notice indicates.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth